Why GSK invested $300 million in 23andMe genetic drug discovery partnership

Pharma giant GlaxoSmithKline simply made a $300 million bet in a consumer genetics company’s capability to find brand-new treatments for clients.

On Wednesday, GSK entered a four-year-long drug development cooperation with cancer tissue or blood, for$2.4 billion a couple of months after it obtained Flatiron Health, another cancer information company, for$1.9 billion.

Anne Wojcicki
23andMe CEO Anne Wojcicki Getty Images/Kimberly White